Short
Celyad Oncology SA
No trades
No trades
0.020 EUR
830.00 K EUR
21.00 K EUR
44.40 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
Website
Headquarters
Mont-Saint-Guibert
Founded
2007
IPO date
Jul 5, 2013
ISIN
BE0974260896
FIGI
BBG004NBYQW1
Identifiers
ISIN BE0974260896
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
Oscillators
Neutral
Summary
Neutral
Summary
Neutral
Summary
Neutral
Moving Averages
Neutral
Moving Averages
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
The current price of CYAD is 0.250 EUR — it has increased by 4.17% in the past 24 hours. Watch Celyad Oncology SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange Celyad Oncology SA stocks are traded under the ticker CYAD.
CYAD stock has fallen by −3.85% compared to the previous week, the month change is a −7.75% fall, over the last year Celyad Oncology SA has showed a −16.67% decrease.
CYAD reached its all-time high on May 25, 2015 with the price of 70.950 EUR, and its all-time low was 0.160 EUR and was reached on Dec 30, 2025. View more price dynamics on CYAD chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CYAD stock is 6.38% volatile and has beta coefficient of 0.71. Track Celyad Oncology SA stock price on the chart and check out the list of the most volatile stocks — is Celyad Oncology SA there?
Today Celyad Oncology SA has the market capitalization of 11.82 M, it has increased by 6.19% over the last week.
Yes, you can track Celyad Oncology SA financials in yearly and quarterly reports right on TradingView.
Celyad Oncology SA is going to release the next earnings report on Sep 23, 2026. Keep track of upcoming events with our Earnings Calendar.
CYAD net income for the last half-year is 4.50 M EUR, while the previous report showed −3.67 M EUR of net income which accounts for 0.00% change. Track more Celyad Oncology SA financial stats to get the full picture.
No, CYAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 22, 2026, the company has 3 employees. See our rating of the largest employees — is Celyad Oncology SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celyad Oncology SA EBITDA is −7.01 M EUR, and current EBITDA margin is −33.38 K%. See more stats in Celyad Oncology SA financial statements.
Like other stocks, CYAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celyad Oncology SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Celyad Oncology SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Celyad Oncology SA stock shows the sell signal. See more of Celyad Oncology SA technicals for a more comprehensive analysis.